Literature DB >> 23625998

The heparin-binding growth factor midkine: the biological activities and candidate receptors.

Kenji Kadomatsu1, Satoshi Kishida, Shoma Tsubota.   

Abstract

The heparin-binding growth factor midkine (MK) comprises a family with pleiotrophin/heparin-binding growth-associated molecule. The biological phenomena in which MK is involved can be categorized into five areas: (i) cancer, (ii) inflammation/immunity, (iii) blood pressure, (iv) development and (v) tissue protection. The phenotypes are clear in vivo, but the mechanisms by which MK exerts these actions are not fully understood. Candidate receptors for MK include anaplastic lymphoma kinase, protein tyrosine phosphatase ζ, Notch2, LDL receptor-related protein 1, integrins and proteoglycans. Some physical associations between these candidate receptors are also known. Because of the striking in vivo phenotypes after manipulation of MK, MK could be an important molecular target for the treatment of various diseases. To this end, it will be important to pursue studies to fully understand the mechanisms of MK action.

Entities:  

Keywords:  ALK; LRP1; PTPζ; cancer; midkine

Mesh:

Substances:

Year:  2013        PMID: 23625998     DOI: 10.1093/jb/mvt035

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  47 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  A glucocorticoid- and diet-responsive pathway toggles adipocyte precursor cell activity in vivo.

Authors:  Janica C Wong; Katherine C Krueger; Maria José Costa; Abhishek Aggarwal; Hongqing Du; Tracey L McLaughlin; Brian J Feldman
Journal:  Sci Signal       Date:  2016-10-25       Impact factor: 8.192

4.  Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics.

Authors:  Yijing Yu; Ioannis Prassas; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

Review 5.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Development of inhibitors of receptor protein tyrosine phosphatase β/ζ (PTPRZ1) as candidates for CNS disorders.

Authors:  Miryam Pastor; Rosalía Fernández-Calle; Bruno Di Geronimo; Marta Vicente-Rodríguez; José María Zapico; Esther Gramage; Claire Coderch; Carmen Pérez-García; Amy W Lasek; Leonor Puchades-Carrasco; Antonio Pineda-Lucena; Beatriz de Pascual-Teresa; Gonzalo Herradón; Ana Ramos
Journal:  Eur J Med Chem       Date:  2017-11-28       Impact factor: 6.514

7.  Lithium chloride has a biphasic effect on prostate cancer stem cells and a proportional effect on midkine levels.

Authors:  Mine Erguven; Gulperi Oktem; Ali Nail Kara; Ayhan Bilir
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

Review 8.  Midkine and cytoplasmic maturation of mammalian oocytes in the context of ovarian follicle physiology.

Authors:  Shuntaro Ikeda; Masayasu Yamada
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 9.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 10.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.